Trial Profile
Examination of the glucose metabolism improvement effects by the combination of DPP-4 inhibitor and SGLT2 inhibitor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2019
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 28 Jan 2019 Status changed from recruiting to completed.
- 21 May 2018 Status changed from not yet recruiting to recruiting.
- 09 Feb 2018 New trial record